-
甲状腺癌是内分泌系统中最常见的恶性肿瘤,其发病率居全球所有恶性肿瘤的第9位[1],90%以上的甲状腺癌为DTC。近年来,DTC的发病率呈持续上升趋势,人群过多暴露于辐射环境、检出率提高等是其可能发病的原因[2-3]。DTC的预后良好,10年生存率可达85%以上[4]。2015年美国甲状腺协会(American Thyroid Association, ATA)发布的《成人甲状腺结节与分化型甲状腺癌诊治指南》[5]指出,131I清甲治疗是DTC患者术后重要的辅助治疗手段。本研究通过分析DTC患者的多项临床指标与131I清甲成功率的关系,探讨影响DTC患者术后首次131I清甲效果的因素,为今后指导DTC患者个体化有效治疗提供理论依据及临床参考。
-
159例DTC患者中,157例为乳头状甲状腺癌、2例为滤泡状甲状腺癌。其中36例接受2.96 GBq131I治疗,91例接受3.70 GBq 131I治疗,29例接受5.55 GBq131I治疗,3例接受7.40 GBq 131I治疗。所有患者均未出现骨髓抑制。
-
159例患者在131I治疗后(4±1)个月复查,按照清甲成功的判断标准,首次清甲的成功患者共112例,首次清甲的成功率为70.4%(112/159)。
-
由表1可知,131I治疗剂量为2.96 GBq组、3.70 GBq组、5.55~7.40 GBq组的清甲成功率的差异有统计学意义(P=0.029)。其中,5.55~7.40 GBq组的清甲成功率高于2.96 GBq组和3.70 GBq组,且差异均有统计学意义(均P<0.05);3.70 GBq组的清甲成功率高于2.96 GBq组,但差异无统计学意义(χ2=1.368,P=0.242)。手术方式为全切的DTC患者的清甲成功率高于近全切患者(P=0.034)。131I治疗前TSH水平≥30 mU/L组患者的清甲成功率高于TSH水平<30 mU/L组的患者(P=0.028)。而性别、年龄、131I治疗前血清Tg水平、131I治疗距离手术的时间的组间清甲成功率的差异均无统计学意义(均P>0.05)。
因素 例数 清甲成功例数
[例(%)]χ2值 P值 性别 2.135 0.144 男 51 32(62.7) 女 108 80(74.1) 年龄 0.311 0.577 <55岁 117 81(69.2) ≥55岁 42 31(73.8) 手术方式 4.502 0.034 全切 128 95(74.2) 近全切 31 17(54.8) 131I治疗前血清Tg水平 3.073 0.080 <10 ng/ml 101 76(75.2) ≥10 ng/ml 58 36(62.1) 131I治疗前血清TSH水平 4.844 0.028 <30 mU/L 25 13(52.0) ≥30 mU/L 134 99(73.9) 131I治疗距离手术的时间 1.186 0.553 <30 d 82 59(72.0) ≥30 d且<60 d 45 29(64.4) ≥60 d 32 24(75.0) 131I治疗剂量 7.071 0.029 5.55~7.40 GBq 32 28(87.5) 3.70 GBq 91 63(69.2)a 2.96 GBq 36 21(58.3)a 注:a表示与5.55~7.40 GBq相比,差异均有统计学意义(χ2=7.158、4.105,P=0.007、0.043)。DTC为分化型甲状腺癌;Tg为甲状腺球蛋白;TSH为促甲状腺激素 表 1 159例DTC患者术后首次131I清甲效果影响因素的分析
Table 1. The analysis of factors influencing the effect of first 131I ablation after operation in 159 differentiated thyroid carcinoma patients
分化型甲状腺癌术后首次131I清甲效果影响因素的分析
Analysis of factors influencing the effect of first 131I ablation after operation with differentiated thyroid cancer
-
摘要:
目的 探讨分化型甲状腺癌(DTC)患者术后首次行131I清甲治疗疗效的影响因素。 方法 回顾性分析2013年4月至2022年3月于河北医科大学第四医院行DTC全切或近全切术后首次行131I 治疗的159例患者的临床资料,其中男性51例、女性108例,年龄24~78(46.5±11.9)岁。将患者按首次行131I治疗的剂量(2.96 GBq、3.70 GBq和5.55~7.40 GBq)分为3组进行研究。按清甲成功的判断标准,即131I 治疗后(4±1)个月131I诊断性全身显像示甲状腺床无放射性浓聚,分析患者的性别、年龄、手术方式、131I治疗前血清甲状腺球蛋白(Tg)水平及促甲状腺激素(TSH)水平、131I治疗距离手术的时间、131I治疗剂量对清甲效果的影响。计数资料的组间比较采用χ2检验。 结果 159例DTC患者首次行131I清甲的成功率为70.4%(112/159)。2.96 GBq组的首次131I清甲成功率为58.3%(21/36),3.70 GBq组为69.2%(63/91),5.55~7.40 GBq组为87.5%(28/32),3组间的差异有统计学意义(χ2=7.071,P<0.05) 。手术方式为全切的DTC患者的清甲成功率为74.2%(95/128),高于近全切患者的54.8%(17/31),且差异有统计学意义(χ2=4.502,P<0.05)。治疗前TSH水平≥30 mU/L患者清甲成功率为73.9%(99/134),高于治疗前TSH水平<30 mU/L患者的52.0%(13/25),且差异有统计学意义(χ2=4.844,P<0.05)。患者在性别、年龄、131I治疗前血清Tg水平以及131I治疗距离手术的时间之间的差异均无统计学意义(χ2=0.311~3.073,均P>0.05)。 结论 131I治疗剂量、手术方式、131I治疗前TSH水平是影响DTC全切或近全切患者清甲成功率的因素。 Abstract:Objective To analyze the affecting factors of the successful rate of first 131I ablation after operation in patients with differentiated thyroid carcinoma (DTC). Methods Clinical data of 159 DTC patients (51 males and 108 females with an age range of 24–78 (46.5±11.9) years) with total thyroidectomy or subtotal thyroidectomy and who received the first 131I ablation in the Fourth Hospital of Hebei Medical University from April 2013 to March 2022 were retrospectively analyzed. The patients were divided into 3 groups according to the doses (2.96 GBq, 3.70 GBq and 5.55–7.40 GBq) of the first 131I treatment. The criteria for successful remnant ablation was as follows: diagnostic whole body scan showing that the thyroid bed had no radioactivity concentration at (4±1) months after 131I ablation. The effects of gender, age, surgical methods, pre-therapeutic thyroid-stimulating hormone (TSH) and thyroglobulin (Tg) levels, the time between operation and 131I ablation, and 131I dosages on efficacy of thyroid remnant ablation were analyzed. χ2 test was used to analyze the counting data. Results Among the 159 DTC patients, the successful rate of thyroid ablation was 70.4% (112/159). The successful rates of thyroid ablation in three treatment groups were 58.3%(21/36) (2.96 GBq group), 69.2%(63/91)(3.70 GBq group), and 87.5%(28/32)(5.55–7.40 GBq group) and the difference was statistically significant (χ2=7.071, P<0.05). The successful thyroid ablation rates in patients with total thyroidectomy were higher than those in patients with subtotal thyroidectomy and the difference was statistically significant (74.2%(95/128) vs. 54.8%(17/31), χ2=4.502, P<0.05). The successful thyroid ablation rate in pre-therapeutic TSH≥30 mU/L patients were higher than those in TSH<30 mU/L patients and the difference was statistically significant (73.9% (99/134) vs. 52.0%(13/25), χ2=4.844, P<0.05). The successful thyroid ablation rates in groups of gender, age, Tg level, and the time between operation and 131I ablation had no significant difference (χ2=0.311–3.073, all P>0.05). Conclusion The 131I dosages, surgical methods, and pre-therapeutic TSH levels are the affecting factors of the success rates of thyroid ablation in DTC patients with total thyroidectomy or subtotal thyroidectomy. -
表 1 159例DTC患者术后首次131I清甲效果影响因素的分析
Table 1. The analysis of factors influencing the effect of first 131I ablation after operation in 159 differentiated thyroid carcinoma patients
因素 例数 清甲成功例数
[例(%)]χ2值 P值 性别 2.135 0.144 男 51 32(62.7) 女 108 80(74.1) 年龄 0.311 0.577 <55岁 117 81(69.2) ≥55岁 42 31(73.8) 手术方式 4.502 0.034 全切 128 95(74.2) 近全切 31 17(54.8) 131I治疗前血清Tg水平 3.073 0.080 <10 ng/ml 101 76(75.2) ≥10 ng/ml 58 36(62.1) 131I治疗前血清TSH水平 4.844 0.028 <30 mU/L 25 13(52.0) ≥30 mU/L 134 99(73.9) 131I治疗距离手术的时间 1.186 0.553 <30 d 82 59(72.0) ≥30 d且<60 d 45 29(64.4) ≥60 d 32 24(75.0) 131I治疗剂量 7.071 0.029 5.55~7.40 GBq 32 28(87.5) 3.70 GBq 91 63(69.2)a 2.96 GBq 36 21(58.3)a 注:a表示与5.55~7.40 GBq相比,差异均有统计学意义(χ2=7.158、4.105,P=0.007、0.043)。DTC为分化型甲状腺癌;Tg为甲状腺球蛋白;TSH为促甲状腺激素 -
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209−249. DOI: 10.3322/caac.21660. [2] Furuya-Kanamori L, Bell KJL, Clark J, et al. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis[J]. J Clin Oncol, 2016, 34(30): 3672−3679. DOI: 10.1200/JCO.2016.67.7419. [3] McGuire S. World cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015[J]. Adv Nutr, 2016, 7(2): 418−419. DOI: 10.3945/an.116.012211. [4] Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables[J]. Clin Oncol (R Coll Radiol), 2010, 22(6): 395−404. DOI: 10.1016/j.clon.2010.05.004. [5] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [6] 林岩松. 分化型甲状腺癌的碘-131治疗现状和进展[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(1): 62−68. DOI: 10.3760/cma.j.issn.1673-0860.2019.01.016.
Lin YS. Postoperative treatment of differentiated thyroid carcinoma with radioiodine-131[J]. Chin J Otorhinolaryngol Head Neck Surg, 2019, 54(1): 62−68. DOI: 10.3760/cma.j.issn.1673-0860.2019.01.016.[7] Verburg FA, Flux G, Giovanella L, et al. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade[J]. Eur J Nucl Med Mol Imaging, 2020, 47(1): 78−83. DOI: 10.1007/s00259-019-04479-1. [8] Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association[J]. Thyroid, 2019, 29(4): 461−470. DOI: 10.1089/thy.2018.0597. [9] Hackshaw A, Harmer C, Mallick U, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review[J]. J Clin Endocrinol Metab, 2007, 92(1): 28−38. DOI: 10.1210/jc.2006-1345. [10] 姜玉艳, 谭建, 张桂芝, 等. 1.1GBq和3.7GBq 131I对中低危分化型甲状腺癌的清甲疗效比较[J]. 中华核医学与分子影像杂志, 2019, 39(9): 526−531. DOI: 10.3760/cma.j.issn.2095-2848.2019.09.004.
Jiang YY, Tan J, Zhang GZ, et al. Comparison between ablation efficacy of 1.1 GBq and 3.7 GBq 131I for low- and intermediate-risk differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imaging, 2019, 39(9): 526−531. DOI: 10.3760/cma.j.issn.2095-2848.2019.09.004.[11] 瞿源, 黄蕤, 董萍, 等. 低剂量和高剂量131I治疗中低危分化型甲状腺癌的随机对照研究[J]. 中华核医学与分子影像杂志, 2016, 36(5): 384−388. DOI: 10.3760/cma.j.issn.2095-2848.2016.05.002.
Qu Y, Huang R, Dong P, et al. Low-dose and high-dose 131I therapy for low and intermediate risk differentiated thyroid cancer: a randomized controlled clinical study[J]. Chin J Nucl Med Mol Imaging, 2016, 36(5): 384−388. DOI: 10.3760/cma.j.issn.2095-2848.2016.05.002.[12] 刘娇, 程兵, 常伟, 等. 非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J]. 国际放射医学核医学杂志, 2016, 40(6): 419−423. DOI: 10.3760/cma.j.issn.1673-4114.2016.06.004.
Liu J, Cheng B, Chang W, et al. Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J]. Int J Radiat Med Nucl Med, 2016, 40(6): 419−423. DOI: 10.3760/cma.j.issn.1673-4114.2016.06.004.[13] 张桂芝, 谭建, 刘雪辉, 等. 131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J]. 中华核医学杂志, 2010, 30(4): 259−263. DOI: 10.3760/cma.j.issn.0253-9780.2010.04.011.
Zhang GZ, Tan J, Liu XH, et al. Influential factors on the effectiveness of 131I treatment on post-surgical differentiated thyroid cancer patients[J]. Chin J Nucl Med, 2010, 30(4): 259−263. DOI: 10.3760/cma.j.issn.0253-9780.2010.04.011.[14] Park HJ, Jeong GC, Kwon SY, et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma[J]. Nucl Med Mol Imaging, 2014, 48(4): 255−261. DOI: 10.1007/s13139-014-0282-4. [15] 王月祺, 黄蕤, 李林. 分化型甲状腺癌术后131I治疗及诊断性显像前提高TSH水平的方案及其影响[J]. 国际放射医学核医学杂志, 2020, 44(1): 59−64. DOI: 10.3760/cma.j.issn.1673-4114.2020.01.012.
Wang YQ, Huang R, Li L. Methods for improving TSH level and their effect in postoperative patients with differentiated thyroid cancer[J]. Int J Radiat Med Nucl Med, 2020, 44(1): 59−64. DOI: 10.3760/cma.j.issn.1673-4114.2020.01.012.[16] 刘晔, 晋建华, 刘建中, 等. 放射性131Ⅰ去除分化型甲状腺癌术后残留甲状腺组织的疗效与影响因素分析[J]. 中国药物与临床, 2013, 13(5): 556−558. DOI: 10.11655/zgywylc2013.05.003.
Liu Y, Jin JH, Liu JZ, et al. Efficacy and influencing factors of radioactive 131I for elimination of thyroid remnants following differentiated thyroid carcinoma resection[J]. Chin Remed Clin, 2013, 13(5): 556−558. DOI: 10.11655/zgywylc2013.05.003.